Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Gourley

Showing results (71-80 of 145) with videos related to

Pageof 15
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
British Journal of Cancer|July 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, Tuan Zea Tan, Jae-Weon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2010
WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosisAdam J W Paige, Manuela Zucknick, Szymon Janczar, et al.
Gynecologic Oncology|September 17, 2011
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancerJudith E Carser, Jennifer E Quinn, Caroline O Michie, et al.
Nature Communications|October 6, 2020
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcomeRobert L Hollis, John P Thomson, Barbara Stanley, et al.
JAMA Oncology|February 6, 2025
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical TrialRebecca Kristeleit, Michael-John Devlin, Andrew Clamp, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
The Journal of Pathology|July 29, 2021
A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinomaValerie Heong, Tuan Z Tan, Maiko Miwa, et al.
Microbial Genomics|July 9, 2026
Reproducible profiling of the gut microbiota using surplus clinical faecal immunochemical test samplesMerel A van den Haak, Jakub T Zbikowski, Aliu Moomin, et al.
Pageof 15

Showing results (71-80 of 145) with videos related to

Sort By:
Pageof 15
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
British Journal of Cancer|July 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, Tuan Zea Tan, Jae-Weon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2010
WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosisAdam J W Paige, Manuela Zucknick, Szymon Janczar, et al.
Gynecologic Oncology|September 17, 2011
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancerJudith E Carser, Jennifer E Quinn, Caroline O Michie, et al.
Nature Communications|October 6, 2020
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcomeRobert L Hollis, John P Thomson, Barbara Stanley, et al.
JAMA Oncology|February 6, 2025
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical TrialRebecca Kristeleit, Michael-John Devlin, Andrew Clamp, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
The Journal of Pathology|July 29, 2021
A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinomaValerie Heong, Tuan Z Tan, Maiko Miwa, et al.
Microbial Genomics|July 9, 2026
Reproducible profiling of the gut microbiota using surplus clinical faecal immunochemical test samplesMerel A van den Haak, Jakub T Zbikowski, Aliu Moomin, et al.
Pageof 15